In-Silico Drug Discovery Market Size, Share & Trends Analysis Report Based on Product (Software, Software-as-a-Service, Consultancy-as-a-Service), Based on Workflow (Discovery, Pre-Clinical Tests, Clinical Tests), Based on Technology (Artificial Intelligence), Based on Target Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Infectious Diseases, Neurological Disorders, Metabolic Disorders, Others), Based on End User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Academic & Research Institutes), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

In-Silico Drug Discovery Market Size

The global in-silico drug discovery market size was valued at USD 3.55 billion in 2025 and is projected to grow from USD 3.92 billion in 2026 to USD 8.68 billion by 2034, registering a CAGR of 10.45% during the forecast period from 2026 to 2034. North America dominated the in-silico drug discovery market with a market share of 42.6% in 2025.

In silico, also known as computer-aided drug design, is a method in which a drug is designed or discovered using computational techniques. New drug molecules that can bind to a specific target are identified through the drug discovery process. This technique for identifying drugs is based on computation, and the entire procedure is regarded as linear and sequential. Several factors make the in-silico drug discovery method more effective and prudent than earlier drug discovery methods employed in the drug development process. In-silico drug design can play a vital role in all phases of drug development, from the initial lead design to the final clinical stage.

Product Insights

The global market can be segmented into technology, workflow, end-users and geographical regions. Artificial Intelligence is the most dominant technology in the market and Software-as-a-service is the most dominant product type of the In-Silico Drug Discovery market.

Request Customizationto receive a tailored report.

Target Therapeutic Area Insights

The market is divided into HIV, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders, autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, and others.

Speak to an Analystto discuss market opportunities.

Regional Insights

The global market for in-silico drug discovery can be segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. During the forecast period, it is anticipated that North America will dominate the global in-silico drug discovery market. During the forecast period, the in-silico drug discovery market in the region is anticipated to be driven by technological advancements, the presence of strong vendors, a large patient population suffering from various chronic and infectious diseases, such as COVID-19 and chronic kidney disease, and a growing government emphasis on improving healthcare infrastructure.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in In-Silico Drug Discovery Market